{"entity":{"id":"nct06411600","kind":"trial","name":"Combination Therapy for BRAF-V600E Metastatic CRCm","aka":["BRAVE"],"tldr":"A phase 2 trial of encorafenib, cetuximab and bevacizumab (glioblastoma use) in colorectal cancer, run by Vall d'Hebron Institute of Oncology, now recruiting.","summary":"Combination Therapy for BRAF-V600E Metastatic CRCm is a phase 2, interventional study registered as NCT06411600 by Vall d'Hebron Institute of Oncology, with a registry enrolment figure of 94 participants, started 2024-05-17 and due to reach its primary completion in 2027-05-01. Interventions recorded: Encorafenib; Cetuximab; Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: \"5 x ULN is allowed if direct (conjugated) ≤1\". Sites: Spain. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06411600","url":"https://clinicaltrials.gov/study/NCT06411600"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["encorafenib","cetuximab","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06411600","phase":"2","setting":"Bevacizumab Plus encoRAfenib-cetuximab in BRAF-V600E Mutated Metastatic Colorectal Cancer, a Phase II Study With a Safety lead-in Cohort, the BRAVE Trial","sponsor":"Vall d'Hebron Institute of Oncology","enrolled":94,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06411600/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}